Fig. 3

MiR-590-3p could target FAM224A and mediate the inhibitory effects of FAM224A knockdown on glioma cells. a. The expression levels of miR-590-3p were downregulated in glioma tissues. Data are presented as the mean ± SD (n = 6, NBTs; n = 8, Grade I; n = 10, Grade II; n = 11, Grade III; n = 14, Grade IV). ^**P < 0.01 vs. NBTs. b. The expression levels of miR-590-3p in NHA, U87 and U251 cells were lowexpressed. Data are presented as the mean ± SD (n = 5, each group). ^**P < 0.01 vs. NHA group. c. The miR-590-3p expression of glioma cells treated with altering FAM224A expression was exhibited. d. The FAM224A expression of glioma cells transfected with miR-590-3p agomir or antagomir was showed. e. The potential miR-590-3p binding sequence and the designed mutant sequence of FAM224A were indicated. f. Relative luciferase activity was detected after cells were co-transfected with pre-miR-590-3p and FAM224A-Wt or FAM224A-Mut. Data were given as mean ± SD (n = 5, each group). ^**P < 0.01 vs. FAM224A-Wt + pre-NC group. g. RIP assay validated that FAM224A and miR-590-3p were involved in an RISC. Data represent mean ± SD (n = 5, each group). ^**P < 0.01 vs. anti-IgG group. h-j. CCK-8 assay, flow cytometry analysis and migration and invasion assays were employed to investigate the biological behaviors of glioma cells co-transfected with sh-FAM224A and miR-590-3p agomir or antagomir. Data are presented as the mean ± SD (n = 5, each group). ^**P < 0.01 vs. FAM224A (−)-NC + pre-NC group. Scale bar of migration and invasion assays represent 40 μm